4D Molecular Therapeutics Says 4D-150 Continues To Be Well Tolerated With No New Safety Findings
FDMT•Company reports updated trial data
- 4DMT announced positive 2-year data from the PRISM Phase 2b clinical trial in a broad wet AMD population.
- 4D Molecular Therapeutics said 4D-150 continues to be well tolerated with no new safety findings.
